Understanding the role of the subthalamic nucleus in Parkinson's disease
Official title: Role of the Subthalamic Nucleus in the Control of Movement: Physiopathology of Akinesia in Parkinson's Disease.
Run by Institut National de la Santé Et de la Recherche Médicale, France · NCT01682668 · Data updated 2026-11-12
This study is testing how a part of the brain called the subthalamic nucleus affects movement in people with Parkinson's disease and whether stimulating it can help improve their motor symptoms.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 180 (estimated) |
| Sponsor | Institut National de la Santé Et de la Recherche Médicale, France Government |
| Locations | 2 sites (Paris, PARIS and 1 other locations) |
| Status | Recruiting |
| Started | February 2013 |
| Main results expected | July 2026 |
| Study ends | August 2026 |
| Registry record updated | July 7, 2026 |
| Trial ID | NCT01682668 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals aged 18 to 70 diagnosed with idiopathic Parkinson's disease who experience motor complications despite optimal medical treatment.
✕Probably not a fit
Patients with contraindications to necessary examinations, significant psychiatric disorders, or dementia may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This program investigates how the subthalamic nucleus (STN) influences movement control in both healthy individuals and those with Parkinson's disease. It aims to explore the dysfunction of the STN and its contribution to akinesia, a common symptom in Parkinson's patients. The study will also assess how stimulation of the STN can improve motor symptoms associated with the disease. Participants will undergo bilateral subthalamic stimulation to evaluate its effects on their motor functions.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies for managing motor symptoms in Parkinson's disease patients.
How similar studies have gone: Previous studies have shown promising results with subthalamic nucleus stimulation in improving motor symptoms in Parkinson's disease, indicating a potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion criteria for patients who will be operated 1. Diagnosis of idiopathic Parkinson's disease (according to the criteria of the United Kingdom Parkinson's Disease Society Brain Bank) 2. Age between 18 and 70; 3. Motor complications in the form of fluctuations in motor state or dyskinesias induced by dopaminergic therapy, despite medical treatment optimum; 4. Other medical conditions that are stable or do not interfere with the procedure proposed; 5. Excellent responsiveness to levodopa (UPDRS motor score improvement greater than 50% in the acute levodopa test) 6. Brain MRI without abnormality 7. Normality of biological examinations 8. Person who has voluntarily and informedly agreed to participate in the study (signature of a written consent) 9. Patient with social health insurance Criteria for non-inclusion of Parkinsonian patients who will be operated 1. Contraindication to examinations necessary for inclusion 2. Evolutionary psychiatric pathology; 3. Dementia(MMS\<24/30); 4. Patients with a medical condition that makes surgery dangerous neuro-surgical; 5. Bleeding-promoting diseases and laboratory test abnormalities clotting; 6. Existence of contraindications to MRI (cardiac or neural pacemaker, clips ferromagnetic surgeries, implants and metal objects, foreign bodies intraocular, pregnancy, claustrophobia). 7. Taking drugs interfering with coagulation for 1 month before intervention. 8. Persons under guardianship, curatorship or any other administrative or judicial measure deprivation of rights and liberty Selection criteria for non-operated patients 1. Diagnosis of idiopathic Parkinson's disease (according to the criteria of the United Kingdom Parkinson's Disease Society Brain Bank); 2. Age between 18 and 70; 3. Other medical conditions that are stable or do not interfere with the proposed protocol; 4. Presence of axial signs (gait and/or balance disorders) no improved by antiparkinsonian treatment 5. Brain MRI without notable abnormality 6. Normality of biological examinations 7. Person who has voluntarily and informedly agreed to participate in the study (signature of a written consent) 8. Patient with social health insurance Criteria for non-inclusion of non-operated patients 1. Contraindication to examinations necessary for inclusion 2. Progressive psychiatric pathology; 3. Dementia (MMS\<24/30); 4. Existence of contraindications to MRI (cardiac or neural pacemaker, clips ferromagnetic surgeries, implants and metal objects, foreign bodies intraocular, pregnancy, claustrophobia). 5. Persons under guardianship, curatorship or any other administrative or judicial measuredeprivation of rights and liberty Inclusion criteria for group 3 patients (already operated) 1. Diagnosis of idiopathic Parkinson's disease (according to the criteria of the United Kingdom Parkinson's Disease Society Brain Bank); 2. Bilateral deep brain stimulation of the subthalamic nucleus for more than 1 year 3. Age between 18 and 70; 4. Person who has voluntarily and informedly agreed to participate in the study (signature of a written consent) 5. Patient with social health insurance Criteria for non-inclusion of Parkinsonian patients (already operated) 1. Contraindication to examinations necessary for inclusion 2. Evolutionary psychiatric pathology; 3. Dementia(MMS\<24/30); 4. Persons under guardianship, curatorship or any other administrative or judicial measure deprivation of rights and liberty Inclusion criteria for healthy subjects 1. Age between 18 and 70 years old 2. Normal neurological examination 3. Person who voluntarily and informedly agreed to participate in the study (signature of a written consent) 4. Patient with social health insurance Criteria for non-inclusion of healthy subjects 1. Persons under guardianship, curatorship or any other administrative or judicial measure of deprivation of rights and freedom 2. Existence of neurological, orthopedic or psychiatric history 3. Existence of contraindications to MRI (cardiac or neural pacemaker, ferromagnetic surgical clips, implants and metallic objects, foreign bodies intraocular, pregnancy, claustrophobia).
Where it's running
-
Groupe Hospitalier Pitie-Salpêtrière
Paris, Paris, France Recruiting -
Cic-Ghps
Paris, France Recruiting
Study contacts
- Principal investigator: Marie-Laure Welter, MD, PhD — GHPS, APHP, Paris, France
- Study coordinator: Marie-Laure Welter, MD, PhD
- Email: marielaure.welter@icm-institute.org
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Ginger as a Modifier of Ghrelin Levels in Parkinson’s Disease and REM Sleep Behavior Disorder
This study tests whether ginger capsules can raise ghrelin levels in people with Parkinson’s disease, REM sleep behavior disorder, and healthy controls.
-
Intraoperative Microelectrode Recordings with MAVEN vs Standard Equipment
This study tests whether MAVEN can match the recording data collected during DBS surgery for movement disorders using standard equipment.
-
Mental imagery with self-regulation to help daily activities in Parkinson's disease
This study tests whether a six-week program of mental imagery combined with self-regulation can help people with Parkinson’s perform daily activities better than standard learning or exercise.
-
Real-world experiences of Inbrija for Parkinson's OFF episodes
This study looks at how people with Parkinson’s who use Inbrija for OFF episodes feel and function in daily life.
-
Gut methane and Parkinson's: measuring if a probiotic helps people with Parkinson's, REM sleep behavior disorder, or cognitive concerns
This study tests whether a probiotic containing Limosilactobacillus reuteri can help people with Parkinson's disease, those at high risk for PD, and related cognitive issues by potentially improving gut methane levels and overall symptoms.
-
Test of RO7568282 in early Parkinson's disease
This study tests whether RO7568282, compared with placebo, is safe and helps people with early Parkinson's disease who are already taking levodopa.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.